BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2014 6:20:00 PM | Browse: 636 | Download: 457
Publication Name World Journal of Hepatology
Manuscript ID 5430
Country/Territory Japan
2013-09-11 08:29
Peer-Review Started
2013-09-11 14:47
To Make the First Decision
2013-10-14 14:07
Return for Revision
2013-10-14 18:08
Second Decision
2013-11-04 16:22
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-11-05 08:32
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-11-11 01:31
Typeset the Manuscript
2013-11-21 14:28
Publish the Manuscript Online
2013-11-26 22:03
ISSN 1948-5182 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title Hepatitis B virus reactivation with rituximab-containing regimen
Manuscript Source Invited Manuscript
All Author List Yutaka Tsutsumi, Yoshiya Yamamoto, Joji Shimono, Hiroyuki Ohhigashi and Takanori Teshima
Funding Agency and Grant Number
Corresponding author Yutaka Tsutsumi, MD, PhD, Department of Hematology, Hakodate Municipal Hospital, Hakodate 1-10-1, Minato-cho, Hakodate 041-8680, Japan. yutsutsu@shore.ocn.ne.jp
Key Words Rituximab; Hepatitis B virus; Reactivation; Chemotherapy; Lamivudine; Non-Hodgkin's lymphoma
Core Tip The deleterious effects of hepatitis B virus (HBV) reactivation in rituximab-containing chemotherapy regimens have been reported and the effect of lamivudine treatment in the prevention of HBV reactivation is also well documented. Once reactivated, HBV may lead to death due to hepatitis. In this review, we discuss the factors of preventive lamivudine treatment (especially in the course of HBV antibody), including to whom and for how long the drug should be given, based on case studies and reports that span rituximab’s debut in 2002 on the Japanese market to June 2013.
Publish Date 2013-11-26 22:03
Citation Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol 2013; 5(11): 612-620
Url http://www.wjgnet.com/1948-5182/full/v5/i11/612.htm
DOI http://dx.doi.org/10.4254/wjh.v5.i11.612
Full Article (PDF) WJH-5-612.pdf
Manuscript File 5430-Review.doc
Answering Reviewers 5430-Answering Reviewers.pdf
Copyright License Agreement 5430-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 5430-Language Certificate.pdf
Peer-review Report 5430-Peer Review(s).pdf
Scientific Editor Work List 5430-Scientific editor work list.doc